Track topics on Twitter Track topics that are important to you
This was an open-label, randomized, multicenter, comparative, parallel-group study comparing the therapeutic effects of two IFN-beta-1a regimens in relapsing-remitting multiple sclerosis. The primary objective was to demonstrate the superiority of Rebi®f 44 mcg SC given three times a week (132 mcg per week) to that of Avonex® 30 mcg IM given once a week.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Multiple Sclerosis, Relapsing-Remitting
Rebif® 44 mcg three times per week subcutaneously (SubQ), Avonex® 30 mcg once weekly intramuscularly (IM)
Published on BioPortfolio: 2014-08-27T03:46:04-0400
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta-1a) in patients with relaps...
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon be...
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta -1a) in patients with rela...
A randomized, multicenter, parallel-group open-label study comparing the tolerability of Rebif® injections (44 mcg administered subcutaneously three times a week) with and without Rebijec...
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central ...
Interferon beta is currently the first line treatment of relapsing-remitting multiple sclerosis (RRMS). Different formulations of interferon beta are available. Avonex and CinnoVex are two interferon ...
Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair it...
The goal of our study was to investigate the cumulative effect of combining medium-energy extracorporeal shock wave therapy (ESWT) and photobiomodulation therapy (PBMT), as well as to compare between ...
Fetuses and neonates are known to be highly susceptible to methylmercury (MeHg) toxicity, but little is known about the relative uptake of MeHg from blood to the developing brain. We measured time-cou...
Reflux following an esophagectomy with gastric conduit reconstruction in the posterior mediastinum is a clinically significant problem. In this study, we investigated the frequency and impact of reflu...
A species of European freshwater LEECHES used for BLOODLETTING in ancient times and also for LEECHING in modern times.
Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.
The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).
The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route.
Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously.